A transpacific biotech rushes toward the clinic with a twist on classic protein degraders

Nicole DeFeudis

Editor

The protein degradation space has erupted in the last few years, with investors goggling at the idea of eliminating problematic proteins via the body’s natural …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A transpacific biotech rushes toward the clinic with a twist on classic protein degraders

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

How AI can address ongoing challenges in the life sciences industry

A transpa­cif­ic biotech rush­es to­ward the clin­ic with a twist on clas­sic pro­tein de­graders

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A transpacific biotech rushes toward the clinic with a twist on classic protein degraders